The combination therapy is the first FDA approved for the mobilization of hematopoietic stem cells prior to autologous transplantation in patients with multiple myeloma. The FDA approved motixafortide ...
- APHEXDA is the first innovation in stem cell mobilization for multiple myeloma to be approved in the U.S. in a decade - - One dosage of APHEXDA plus filgrastim enabled a majority of patients to ...
Factors affecting the hematological and nonhematological toxicities in B-cell lymphoma patients during treatment No significant financial relationships to disclose. This is an ASCO Meeting Abstract ...
Gary Lyman, MD, MPH, an oncologist and hematologist, compares the uptake of filgrastim biosimlars with pegfilgrastim biosimilars. Gary Lyman, MD, MPH, is an oncologist, hematologist, and public health ...
Neulasta (pegfilgrastim) is a brand-name drug that’s prescribed to treat radiation sickness and prevent certain complications of chemotherapy. Neulasta comes as an injectable solution. The dosage can ...
Clinical data from randomized studies demonstrated that Filkri is highly similar to the reference product with no clinically meaningful differences in safety, pharmacokinetics, or immunogenicity. The ...
Balugrastim: A long-acting, once-per-cycle, recombinant human albumin-fusion filgrastim. This is an ASCO Meeting Abstract from the 2013 ASCO Annual Meeting I. This abstract does not include a full ...
Releuko ® (filgrastim-ayow), a biosimilar to Neupogen ® (filgrastim), is now available in the US for the treatment of neutropenia. Releuko, a leukocyte growth factor, is indicated to: Decrease the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results